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ABSTRACT
The risk of transmission of transmissible spongiform encephalopathies (TSE) between different species has been notoriously
unpredictable because the mechanisms of transmission are not fully understood. A transmission barrier between species often
prevents infection of a new host with a TSE agent. Nonetheless, some TSE agents are able to cross this barrier and infect new spe-
cies, with devastating consequences. The host PrPC misfolds during disease pathogenesis and has a major role in controlling the
transmission of agents between species, but sequence compatibility between host and agent PrPC does not fully explain host sus-
ceptibility. PrPC is posttranslationally modified by the addition of glycanmoieties which have an important role in the infectious
process. Here, we show in vivo that glycosylation of the host PrPC has a significant impact on the transmission of TSE between
different host species. We infected mice carrying different glycosylated forms of PrPC with two human agents (sCJDMM2 and
vCJD) and one hamster strain (263K). The absence of glycosylation at both or the first PrPC glycosylation site in the host results
in almost complete resistance to disease. The absence of the second site of N-glycan has a dramatic effect on the barrier to trans-
mission between host species, facilitating the transmission of sCJDMM2 to a host normally resistant to this agent. These results
highlight glycosylation of PrPC as a key factor in determining the transmission efficiency of TSEs between different species.
IMPORTANCE
The risks of transmission of TSE between different species are difficult to predict due to a lack of knowledge over the mecha-
nisms of disease transmission; some strains of TSE are able to cross a species barrier, while others do not. The host protein, PrPC,
plays a major role in disease transmission. PrPC undergoes posttranslational glycosylation, and the addition of these glycans
may play a role in disease transmission.We infected mice that express different forms of glycosylated PrPC with three different
TSE agents. We demonstrate that changing the glycosylation status of the host can have profound effects on disease transmis-
sion, changing host susceptibility and incubation times. Our results show that PrPC glycosylation is a key factor in determining
risks of TSE transmission between species.
Transmissible spongiform encephalopathies (TSE), or priondiseases, are fatal neurodegenerative diseases that can be spo-
radic, genetic, or acquired by infection (1). These diseases are
characterized by a distinct pathology in the central nervous system
(CNS), with neuronal loss, spongiform degeneration, and gliosis
(2). Numerous mammalian species are susceptible to infection
with TSE agents, such as scrapie in sheep and goats, bovine spon-
giform encephalopathy (BSE) in cattle, Creutzfeldt-Jakob disease
(CJD) in humans, and chronic wasting disease (CWD) in cervids.
The host cellular protein PrPC has been shown to have a key
role in the transmission of disease (3, 4). During the disease pro-
cess, PrPC misfolds from the normal conformation to an aberrant
form (PrPSc), which is partially resistant to proteases. The prion
hypothesis proposes that PrPSc is the infectious agent responsible
for disease transmission and that it is able to self-propagate and
induce TSE disease in a new host in the apparent absence of any
nucleic acid (5).
Transmission of TSE between different species often is limited
by a species barrier to infection (6, 7). In experimental models of
disease, the species barrier is characterized by an inefficient pri-
mary infection with low susceptibility and long incubation times
in the new host. Adaptation to the new host then usually occurs in
subsequent passages with an increased attack rate and shorter in-
cubation time (6, 8). In naturally occurring TSE, the species bar-
rier prevents transmission of certain agents between different spe-
cies. However, some agents have been shown to be able to cross
this barrier and cause devastating epidemics in a new host. For
example, BSE in cattle can be transmitted to humans via the oral
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route to cause variant CJD (vCJD) (9, 10). BSE also was able to
naturally infect a number of different species, such as goats, nyala,
kudu, and domestic or captive wild cats (11–13). Understanding
how the species barrier is regulated is important, so that the
zoonotic potential of a TSE in other animal populations trans-
mitting to humans can be assessed. This is particularly impor-
tant for newly emergent strains of TSE in both farmed and wild
animals (8, 14).
Despite many studies in recent decades, the mechanisms reg-
ulating the species barrier to TSE transmission still are elusive. It
has been proposed that sequence identity between host and donor
PrPC is important to determine the barrier to transmission. In
particular, evidence suggests that sequence homology between
host PrPC and PrPSc leads to high susceptibility and shorter incu-
bation time, whereas sequence differences between these two pro-
teins can lead to lower susceptibility of the host (6, 15, 16). How-
ever, this is not always the case (17–19), and it becomes difficult to
predict the transmissibility of a strain in a new recipient based
solely on sequence identity between host and donor. It is likely
that other factors should be taken in account to understand and
predict the species barrier.
PrPC is variably glycosylated at two highly conserved sites
(amino acid positions 180 and 196 inmice). N-glycan attachment
to these sites results in four glycosylated forms (glycotypes) of PrP,
diglycosylated, monoglycosylated at position 180, monoglycosy-
lated at position 196, and unglycosylated. While the ratios of dig-
lycosylated, monoglycosylated, and unglycosylated PrPC remain
reasonably constant in uninfected brains, the ratios of PrPSc are
highly variable in brains infected with different TSE agents.
In vitro studies have demonstrated that the choice of mutation
at the glycosylation sites can have profound effects on PrP traffick-
ing, preventing infection of the resulting mutant mice (20). In
order to define the role of glycosylation in the transmission of
disease, glycosylation-deficient mice have been produced by three
laboratories, and inoculations with a number of TSE agents de-
rived from the same species have been carried out (20–22). Con-
ventional transgenic mice expressing hamster PrP in which the
first N-glycan site (T183A) or both the first and second site
(T183A, T199A) were disrupted were resistant to hamster-pas-
saged prion strains Sc237 and 139H. Mice devoid of the second
site also were resistant to 139H but susceptible to Sc237, with
extended incubation periods compared to those of the controls
(21). In contrast, transgenic mice expressing a 3F4-taggedmurine
PrP devoid of the first site (T182N) showed no evidence of resis-
tance to any of the murine agents ME7, 139A, and murine-pas-
saged BSE (301C) (20). Mice lacking the second site (T198A) also
were susceptible to these strains with extended incubation times
(20). Cancellotti et al. produced three inbred lines of gene-tar-
getedmice inwhich the first (G1;N180T), second (G2;N196T), or
both (G3; N180T and N196T) N-glycan attachment sites were
disrupted. The homozygous transgenic mice produce partially or
unglycosylated PrPC under the control of the endogenous mouse
Prnp promoter (22). Mice lacking the first N-glycan site were sus-
ceptible to 79A, but unlike those of Neuendorf et al., they were
resistant to ME7. Mice lacking the second site were susceptible to
a number of TSE strains, including ME7, 79A, and 301C, similar
to those of Neuendorf et al. However, extended incubation peri-
ods were observed for all strains inNeuendorf et al. but only in the
case of 301C in Tuzi et al. (20, 23). The differences between
the lines ofmice can be attributed tomany variables, including the
different point mutations used to disrupt the glycosylation sites,
the species of origin of the PrP gene, different gene constructs, the
addition of epitopes, copy numbers, and integration sites, and
strain differences of the inocula. The gene-targeted mice, how-
ever, remove at least some of the variability observed with the
conventional lines of mice.
Multiple strains of TSE agents have been identified. Strains
differ in their disease characteristics, such as their transmissibility
to other host species or the degree of pathology induced in the
brain of the host (24–26). These different strains are proposed to
result from different conformations of PrPSc (27–29). The ratio of
the glycotypes of PrPSc also differs between TSE strains (30, 31).
For example, PrPSc associated with vCJD is predominately digly-
cosylated, whereas that associated with sporadic CJD (sCJD) is
mostly monoglycosylated (32). The N-glycans attached to PrP
may influence the conformational flexibility of the protein and
could influence its misfolding (33, 34). Conformational flexibility
may be particularly important during interspecies transmission of
TSE, as the infectious agent must adapt to the novel source of
PrPC. Indeed, in vitro interspecies misfolding of PrPC induced by
PrPSc is inhibited specifically by glycosylation of the protein (35).
Moreover, the replication of a given strain may require the
misfolding of a precise combination of PrPC glycotypes to rep-
licate the glycoform (36). For example, the replication of a
strain in which PrPSc is predominately monoglycosylated may
be favored in a host that produces an elevated level of monogly-
cosylated PrPC.
Here, we have tested the effect of host PrPC glycosylation on the
TSE species barrier. This is the first in vivo study of the role of
glycosylation of PrPC on the transmission of TSE agents between
species. Previous in vitro and in vivo studies to investigate this issue
have provided inconsistent results (35, 37, 38) or used mouse-
passagedTSE agents (20, 21). Some studies have suggested that the
glycosylation of PrPC impedes the transmission between host spe-
cies (35), whereas others have shown no such effect (20, 38).
We challenged three lines of gene-targeted glycosylation mu-
tants (22) with three nonmurine TSE agents: human vCJD, hu-
man sCJD (sCJDMM2), and hamster scrapie 263K. These agents
differ in their PrPSc glycoform ratios and their relative transmissi-
bility to wild-type mice (9, 39, 40). Two of the agents used in this
study (263K and vCJD) have similar PrPSc glycoform ratios in
which PrPSc is predominately diglycosylated. The sCJDMM2
agent has an amino acid sequence identical to that of the vCJD
agent and a cleavage site similar to that of proteinase K (PK);
however, it has a significantly different PrPSc glycoform ratio, as
the PrPSc associated with this agent is predominately monoglyco-
sylated. By comparing the relative transmissibility of these TSE
agents to our transgenic models, we have established the impor-
tance of host PrPC glycosylation in determining the transmissibil-
ity of a TSE strain across a species barrier.
MATERIALS AND METHODS
Preparation of TSE inocula and intracerebral injection. Inocula were
prepared from brain tissue from a patient with pathologically confirmed
sCJDMM2 (0.1% [wt/vol] in physiological saline), the National Institute
for Biological Standards and Control (NIBSC) variant CJD reference case
(0.1% [wt/vol] in physiological saline), and a hamster with clinical
scrapie, strain 263K (1% [wt/vol] in physiological saline). Consent for the
use of these materials for research was obtained with ethics approval by
the Lothian National Health Service Research Ethics Committee (refer-
ence no. 2000/4/157). G1 (N180T), G2 (N196T), andG3 (N180T,N196T)
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transgenic and wild-type mice were genotyped by mismatched PCR as
previously described (22) and coded prior to intracerebral (i.c.) injection
with 20 l of inoculum. All groups were age and sex matched.
The second passage was carried out in a similar manner using brain
material from selected G2 and wild-type mice showing evidence of TSE
vacuolation and/or PrP deposition. A second passage was not carried out
in G1 or G3 mice due to extremely low numbers of mice exhibiting TSE
vacuolation and/or PrP deposition. Inocula were prepared from mouse
brain tissue at 0.1% (wt/vol) in physiological saline, and mice were inoc-
ulated via the i.c. route with 20l. Animal experiments were approved by
The Roslin Institute’s Ethical Review Board and were conducted accord-
ing to the regulations of the 1986 United KingdomHome Office Animals
(Scientific Procedures) Act.
Scoring of clinical TSE disease and pathology. Mice were scored
weekly for clinical signs from 100 days postinoculation (dpi) by operators
blind to animal genotype according to a previously established TSE clin-
ical scoring system (41).Mice were scored as unaffected, possibly affected,
or definitely affected using standard criteria, including kyphosis, ataxia,
paralysis, hyperactivity, urinary incontinence, and weight loss. Any un-
usual clinical signs were noted. In older animals, signs of aging (kyphosis,
weight loss, and reduced activity) were taken into account and were clas-
sified as possibly affected due to the similar nature of aging and TSE
disease phenotypes. Mice were sacrificed after (i) two consecutive scores
of definitely affected, (ii) after receiving scores of definitely affected in 2
out of 3 weeks, or (iii) significant deterioration of condition.Mice with no
signs of clinical disease were maintained until approximately 700 dpi, at
which point the studies were terminated. Animals in which clinical signs
were present without pathological (TSE vacuolation and/or PrP deposi-
tion) confirmationwere removed from the analysis, as these signs also can
be due to other conditions, such as aging, as detailed above. Incubation
periods were calculated as the number of days between injection and the
clinical endpoint in animals with TSE vacuolation. In the absence of an
incubation period, the survival time was calculated in days.
Half brains were fixed in formal saline for 48 h and decontaminated
with formic acid, when required, prior to paraffin embedding. Coronal sec-
tions were cut and stained with hematoxylin and eosin, and TSE-specific
vacuolation was semiquantitatively scored blind to TSE strain and mouse
genotype by standard methods (42). Vacuolation profiles were plotted for
groupsof 6miceormore.Genotypes of allmicewere confirmedpostmortem
by PCR (22). Early intercurrent deaths (under 200 dpi for the first pass and
100 dpi for the second pass) were excluded from the study.
Biochemical assessment of PrPSc in first-passmice.Half brains from
mice challenged with either sCJDMM2, vCJD, or 263K were used to pre-
pare a 1% (wt/vol) inocula in physiological saline; from this, PrPSc was
extracted using extraction buffer (NP-40, sodium deoxycholate, sodium
chloride, Tris [pH 7.4]) and digested with PK (37°C for 1 h, 20 g/ml).
Reactions were terminated by the addition of phenylmethylsulfonyl fluo-
ride. If required, PrPSc thenwas concentrated by sodiumphosphotungstic
acid (NaPTA)-mediated precipitation (43). Samples (brain homogenate/
NaPTA-concentrated PrPSc) were analyzed for PrPSc byWestern blotting
using the anti-PrP antibody 8H4 (1/10,000) (44). PrPSc could not be easily
detected in vCJD-challengedG2mice. In order to detect PrPSc inG2mice,
NaPTA-mediated precipitation was carried out on 10% (wt/vol) brain
homogenates such that the equivalent of 5g of total brainwas runperG2
well. Equal PrP signal then was achieved by diluting wild-type PrPSc 10-
fold prior to electrophoresis.
Immunohistochemistry. Coronal brain sections were stained using
the 6H4 antibody (1/20,000; Prionics) to detect PrP. Antigen retrieval by
autoclaving at 121°C for 15min and a 5-min formic acid (98%) treatment
was used. Sections then were blocked with normal rabbit serum prior to
incubation with the primary antibody. Antibody binding was detected
with either the catalyzed signal amplification system (Dako) or Vector
ABCkit (Vector Laboratories) and visualizedwith 3,3=-diaminobenzidine
chromogen. All sections were counterstained with hematoxylin. In all
experiments, normal brain homogenate-inoculated mouse and PrP/
mouse (NPU, Edinburgh, United Kingdom) sections were used as a neg-
ative control (4).
Biochemical assessment of PrPC in uninfected glycosylation-defi-
cient transgenic mice. Brains from uninfected G1, G2, G3, and wild-type
micewere used to prepare 10%(wt/vol) homogenates. An-tubulin load-
ing control was included to determine variation in the amount of protein
being loaded. Samples were analyzed by Western blotting using seven
primary anti-PrP antibodies (7A12/epitope, conformation epitope; DE3/
epitope, aa146-153; FH10/epitope, aa202-210; AE11/epitope, aa140-145;
BH1/epitope, aa143/154; FD12/epitope, unknown at 0.1g/ml; and BC6/
epitope, aa146-156 at 0.01 mg/ml) (45, 46) and species-specific peroxi-
dase-conjugated AffiniPure antibodies (Stratech) at 0.05g/ml diluted in
0.5% blocking solution for 30 min at room temperature. Bound second-
ary antibody was detected by light emission from SuperSignal West Dura
chemiluminescent substrate using a Kodak 440 Image Stationwith typical
exposures of 1, 5, and 10min. Immunoblots were imaged using the Kodak
Image Station and Kodak MI software. Protein bands were selected man-
ually by drawing around them and the sum intensity calculated. A blank
region also was selected to measure the background intensity of the blot.
RESULTS
Absence of the first and both PrPC glycosylation sites limits
transmission with all three agents. Infection of G1 and G3 mice
with vCJD and sCJDMM2 resulted in nopathologically confirmed
clinical disease and no evidence of TSE vacuolation and/or PrP
deposition in the brain (Tables 1 and 2). While there were a num-
TABLE 1 Sporadic CJDMM2 inoculation into glycosylation-deficient mice at first and seconda passages
Mouse
line Inoculum
Incubation timeb (days)
SEM (range)
Clinical disease (no.
positive/total no.)
TSE vac and/or PrP
depositionc
Survival time (days) of
mice with TSE vac
and/or PrPd
G1 sCJDMM2 0/18 0/18
G2 sCJDMM2 404 8 (378–430) 7/20 11/20 367 50 (245–494)
G3 sCJDMM2 0/18 0/18
Wt sCJDMM2 0/41 3/41 658 49 (559–707)
G2 G2sCJDa 129 3 11/11 11/11
Wt G2sCJDa 430 20 12/12 12/12
G2 G2sCJDb 147 3 10/11 11/11
Wt G2sCJDb 439 22 10/10 10/10
a Brain material from two sCJDMM2-inoculated G2 mice with pathological evidence of disease were further passaged into G2 and wild-type mice.
b Incubation time for mice with clinical signs and evidence of TSE vacuolation. Studies were maintained to700 dpi for mice with no clinical signs of TSE disease.
c TSE vacuolation (vac) and/or PrP deposition were used as evidence of transmission for primary passage due to low numbers of mice with clinical signs and vacuolation present.
Limited confirmatory immunohistochemistry for PrP deposition was carried out in the second passage due to high numbers of mice with clinical signs and vacuolation present.
d Survival time of mice with no clinical signs and evidence of vacuolation and/or PrP deposition.
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ber ofG1mice (4/14)with TSE vacuolation and/or PrP deposition
after 263K infection, again therewere no cases of clinical disease or
TSE vacuolation and/or PrP deposition in G3 mice (Table 3).
Thus, the absence of either the first or both PrPC glycosylation
sites in the host appears, particularly in the case of vCJD and
sCJDMM2, to restrict replication of the agent within the CNS
compared to that of the wild-type mice.
Absence of sugars at the second glycosylation site of PrPC in
the host removes the barrier to infection with sCJD. G2 trans-
genic mice were susceptible to sCJDMM2, in contrast to the G1,
G3, and wild-typemice (Table 1; also see Fig. 2D). Seven out of 20
of the sCJDMM2-challenged G2 transgenic mice developed clin-
ical diseasewith an average incubation time of 404 8 days (Table
1). Disease status was confirmed by pathology within the brain in
which both TSE vacuolation and PrP deposition were observed
(Fig. 1A and 2A). PK-resistant PrPSc also was detected byWestern
blotting in brains of thesemice (Fig. 3A). Themolecular weight of
PrPSc in these samples is consistent with the majority of PrPSc
being monoglycosylated, as observed in previous studies using
these mice (23). Thus, removal of the second glycosylation site of
the host PrPC has rendered the host susceptible to cross-species
transmission with sCJDMM2.
Brain material from two G2 mice that had developed clinical
disease following inoculation with sCJDMM2 (G2-sCJD) was
used to challenge G2 and wild-type mice. All challenged G2 mice
rapidly developed a clinical disease with remarkably short incuba-
tion times of 129 3 days and 147 3 days (Table 1). Wild-type
mice that previously were resistant to infection with the
sCJDMM2 agent developed a clinical disease after challenge with
G2-sCJD brain; however, in this case the incubation time was
much longer than that for G2 recipients (430 20 days and 439
22 days) (Table 1).
The pathological signs of disease differed in the two hosts, with
the vacuolation profile in G2 mice distinct from that observed in
wild-type mice (Fig. 1B). The intensity of TSE vacuolation in the
superior colliculuswas lower inG2mice than inwild-type animals
infected with G2-sCJD brainmaterial. More intense TSE vacuola-
tion occurred in the cingulate cortex of the G2 mice than in wild-
type animals after challenge with G2-sCJD brain material (Fig.
1B). Primary and secondary passage of sCJDMM2 in G2 mice
TABLE 2 Variant CJD inoculation into glycosylation-deficient mice at first and seconda passages
Mouse
line Inoculum
Incubation timeb (days)
SEM (range)
Clinical disease (no.
positive/total no.)
TSE vac and/or PrP
depositionc
Survival time (days) of mice
with TSE vac and/or PrPd
G1 vCJD 0/17 0/17
G2 vCJD 536 16 (510–600) 8/18 14/18 611 29 (505–708)
G3 vCJD 0/19 0/19
Wt vCJD 477 15 (380–616) 21/40 36/40 483 18 (310–616)
G2 G2vCJDa 283 3 10/11 11/11
Wt G2vCJDa 192 2 12/12 12/12
G2 G2vCJDb 315 3 11/12 12/12
Wt G2vCJDb 193 3 12/12 12/12
G2 WtvCJD 334 6 11/13 13/13
Wt WtvCJD 156 1 12/12 12/12
a Brain material from two vCJD-inoculated G2 mice and one vCJD inoculated wild-type mouse with pathological evidence of disease were further passaged into G2 and wild-type
mice.
b Incubation time for mice with clinical signs and evidence of TSE vacuolation. Studies were maintained to700 dpi for mice with no clinical signs of TSE disease.
c TSE vacuolation and/or PrP deposition were used as evidence of transmission for primary passage due to low numbers of mice with clinical signs and vacuolation present. Limited
confirmatory immunohistochemistry for PrP deposition was carried out in the second passage due to high numbers of mice with clinical signs and vacuolation present.
d Survival time of mice with no clinical signs and evidence of TSE vacuolation and/or PrP deposition.
TABLE 3 263K inoculation into glycosylation-deficient mice at first and second passagesa
Mouse
line Inoculum
Incubation timeb (days)
SEM (range)
Clinical disease (no.
positive/total no.)
TSE vac and/or PrP
depositionc
Survival time (days) of mice
with TSE vac and/or PrPd
G1 263K 0/14 4/14 579 35 (507–674)
G2 263K 0/18 11/18 552 18 (461–629)
G3 263K 0/16 0/16
Wt 263K 0/18 11/18 612 18 (503–698)
G2 G2–263Ka 284 7 12/12 12/12
Wt G2–263Ka 437 32 10/12 9/12
G2 G2–263Kb 320 7 11/11 11/11
Wt G2/263Kb 536 6 4/10 6/10 343 61 (282–408)
G2 Wt263K 365 0 11/12 12/12
Wt Wt263K 172 5 9/10 10/10
a Brain material from two 263K-inoculated G2 mice and one 263K-inoculated wild-type mouse with pathological evidence of disease were further passaged into G2 and wild type
mice
b Incubation time for mice with clinical signs and evidence of TSE vacuolation. Studies were maintained to700 dpi for mice with no clinical signs of TSE disease.
c TSE vacuolation and/or PrP deposition were used as evidence of transmission for primary passage due to low numbers of mice with clinical signs and vacuolation present. Limited
confirmatory immunohistochemistry for PrP deposition was carried out in the second passage due to high numbers of mice with clinical signs and vacuolation present.
d Survival time of mice with no clinical signs and evidence of TSE vacuolation and/or PrP deposition.
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showed a similar trend in vacuolation intensity throughout the
brain (Fig. 1A and B). The lack of the second glycosylation site in
the host appears to greatly facilitate the infection with sCJD, sug-
gesting that the diglycosylated form of host PrP is important in
maintaining the species barrier of a predominantly monoglycosy-
lated strain.
Diglycosylated PrPC in the host influences incubation time
in the interspecies transmission of vCJD. Variant CJD PrPSc has
FIG1 Lesion profile analysis of wild-type (Wt) andG2mice after intracerebral inoculationwith sCJDMM2 (A), second passage of sCJDMM2 (B), vCJD (C), and
second passage of vCJD (D). The second passage was carried out from selected G2 and wild-type mice showing TSE vacuolation and/or PrP. Group size, n 6
( standard errors of the means). Gray matter scoring regions are labeled G1 to G9: G1, dorsal medulla; G2, cerebellar cortex; G3, superior colliculus; G4,
hypothalamus;G5, thalamus;G6, hippocampus;G7, septum;G8, retrosplenial cortex; G9, cingulate and adjacentmotor cortex.White-matter scoring regions are
labeled W1 to W3: W1, cerebellar white matter; W2, mesencephalic tegmentum; W3, pyramidal tract.
FIG2 PrP deposition in the brains of wild-type andG2mice after intracerebral inoculationwith sCJDMM2, vCJD, or 263K agent. (A)G2mouse inoculatedwith
sCJDMM2; (B) G2 mouse inoculated with vCJD; (C) G2 mouse inoculated with 263K; (D) wild-type mouse inoculated with sCJDMM2; (E) wild-type mouse
inoculated with vCJD; (F) wild-type mouse inoculated with 263K. Arrows indicate examples of PrP accumulation in the form of plaque-like deposits in panels
A and B and examples of fine punctate PrP accumulation in panels C, E, and F. No PrP accumulation was detected in panel D. PrP was detected with 6H4
antibody. dg, dentate gyrus; cc, corpus callosum. Scale bars, 500 m.
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an identical amino acid sequence and PK cleavage pattern by
Western blotting similar to that of PrPSc from sCJDMM2 but is
predominately diglycosylated compared with the predominantly
monoglycosylated sCJDMM2. Moreover, vCJD has been shown
to transmit readily to wild-type mice, in contrast to sCJDMM2.
Twenty-one out of 40 wild-type mice challenged with vCJD
developed clinical disease with an average incubation time of
477  15 days. A similar proportion of G2 mice (8/18) devel-
oped clinical disease, with an average incubation time of 536
16 days (Table 2).
The pattern of TSE vacuolation was similar in G2 transgenic
and wild-type mice infected with vCJD (Fig. 1C). However, as
shown in Fig. 2B and E, there is less PrP deposition in the brains of
animals expressing monoglycosylated PrP (G2) than in those of
the wild-type mice. Diffuse deposition of PrP was observed in the
brains of wild-typemice. In contrast, small plaque-like deposits of
PrP were observed in the brains of G2 transgenic mice. In order to
detect PrPSc in the G2mouse brain, NaPTA precipitation of PrPSc
was required, followed by equalized PrPSc loading (5 g of G2
brain versus 1g of wild-type brain), indicating that there was less
PrPSc in G2 mice than in wild-type mice (Fig. 3B).
To further investigate the effect of the second site on vCJD
transmission, we inoculated brain material from two G2 mice
(G2-vCJD with monoglycosylated PrPSc) and a wild-type mouse
(Wt-vCJD with fully glycosylated PrPSc) previously infected with
vCJD intoG2 andwild-type recipients.Wild-typemice expressing
fully glycosylated PrPC developed clinical disease within 192  2
days and 193  3 days of infection with two independent G2-
vCJD isolates. Two groups of G2 mice that were challenged with
these isolates developed clinical disease later than the wild-type
controls (283 3 days and 315 3) (Table 2). The same pattern
also was observed when mice were challenged with the Wt-vCJD
brainmaterial; G2mice developed a clinical disease later (334 6
days) than wild-type mice (156  1 days) (Table 2). Despite
changes in incubation times, the pattern of TSE vacuolation ap-
peared to be similar between G2 and wild-type mice and between
primary and secondary passages of vCJD (Fig. 1C and D).
Glycosylation compatibility between the hamster strain
263K and host PrPC reduces the species barrier. Primary trans-
mission was carried out with the hamster TSE strain 263K. PrPSc
associatedwith the 263K agent is predominately diglycosylated. In
contrast to vCJD, wild-type mice do not develop a clinical disease
with this TSE strain but do show evidence of PK-resistant PrPSc in
the brain following inoculation (39, 47). After challenge with
263K, no wild-type or G2 mice exhibited clinical disease, consis-
tent with previous data. However, both G2 and wild-type mice
demonstrated pathological signs of a subclinical infection (G2,
11/18; wild type, 11/18) (Table 3 and Fig. 2C and F). PK-resistant
PrPSc also was detected in the brains of these mice by Western
blotting (Fig. 3C). The PrPSc glycoprofile in these samples is con-
sistent with the majority of PrPSc being monoglycosylated in G2
recipients and fully glycosylated in wild types.
G2 and wild-type mice were challenged by an i.c. route with
brain homogenate from two 263K-inoculated G2 mice (G2-263K
withmonoglycosylated PrPSc) and a 263K-infected wild-typemouse
(Wt-263K with fully glycosylated PrPSc). In contrast to the vCJD
transmissions, G2 mice had a higher susceptibility to disease after
challenge with G2-263K than wild-type mice; all G2 mice suc-
cumbed to disease after challenge, whereas 10/12 (with the first G2
brain) and 4/10 (with the second G2 brain) wild-type mice devel-
oped clinical signs of TSE disease after G2-263K infection (Table
3). Moreover, G2 mice developed disease more quickly (284 7
days and 320  7 days) than wild-type mice (437  32 days and
536 6 days) after challenge with G2-263K (Table 3). The differ-
ences in the attack rate and incubation periods elicited by the two
isolates of G2-263K may occur because the two animals from
which they were derived were at different stages of subclinical
infection; hence, they had different titers of infectivity within their
brains. The G2 mice challenged with Wt-263K developed disease
later (365 0 days) than wild-typemice (172 5 days) (Table 3).
Thus, 263K transmits with similar efficiency in the G2 mice and
the wild-typemice in the primary passage, but unlike vCJD on the
second passage following G2 transmission, this agent was consid-
erably faster in the G2 host than in the wild-type host.
PrPC expression is reduced in glycosylation-deficient mice.
To ascertain whether the protein levels of PrPC in any of the lines
of mice could influence the incubation times in the transmissions
described above, we undertook analysis of the PrPC levels in all
mouse lines. Immunoblot analysis showed the expected banding
FIG 3 Biochemical analysis of PrPSc from the brains of G2 andwild-type (Wt)
mice inoculated with sCJDMM2, vCJD, and 263K. (A) PrPSc was isolated from
four sCJD-challenged G2 mice, one vCJD-challenged G2 mouse (assayed in
duplicate), and one vCJD-challenged wild-type mouse (assayed in duplicate)
by standard PK digestion. PrPSc was concentrated by NaPTA precipitation.
The amount of PrPSc in the vCJD-challenged G2 sample was too low to detect.
Uninfected mice and a 263K-challenged wild-type mouse were included as
controls. (B) PrPSc was isolated from vCJD-challenged G2 mice by standard
PK digestion followed by NaPTA precipitation. The amount of PrPSc was
equalized by dilution following NaPTA precipitation to allow comparison
(equivalent of 5g of G2 brain and 0.5 to 1g of wild-type brain). Uninfected
mice were included as controls. (C) PrPSc was isolated from three 263K-chal-
lengedG2mice and threewild-typemice by standardPKdigestion.Uninfected
mice and a 263K-challenged hamster were included as controls. The different
isoforms of PrP are denoted Di (for diglycosylated), Mono (monoglycosy-
lated), and Un (unglycosylated). PrPSc was detected with 8H4.
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patterns for both the transgenic and wild-type mice. Truncated
PrPC, designated C1, was observed in all mice and was included in
the measurement of total PrPC (selected antibodies are shown in
Fig. 4A and B). All of the glycosylation-deficient mice expressed
significantly less PrPC than wild-type mice (P 0.0001). G1 and
G2 mice expressed approximately 50% and G3 mice only 32% of
that found in wild-type mice, with G3 mice expressing signifi-
cantly less (P  0.01) than both G1 and G2 mice. There was no
significant difference in total PrP in each mouse line using differ-
ent antibodies (Fig. 4A and B).
DISCUSSION
Expression of PrPC is known to influence incubation times of a
TSE disease, with reduced levels of the protein resulting in longer
incubation periods (48). Earlier studies showed conflicting results
over whether PrPC expression levels are altered within the glyco-
sylation transgenic mice (22). This most likely was due to the
epitope recognition of the antibodies used and detection of only a
subset of isoforms. Our expanded studies here, using a range of
monoclonal antibodies within the C-terminal and central region
of PrPC, are able to detect all isoforms of PrPC, demonstrating that
G1, G2, and G3mice do have lower levels of PrPC expression than
wild-typemice. However, while lower levels of PrPC in the G1 and
G3 mice may contribute to longer incubation times, the levels
observed in these mice are not likely to explain the resistance to
TSE disease observed here. Studies have shown that mice
heterozygous for PrPC expression and with a level of PrPC expres-
sion similar to that of the G1 mice are fully susceptible to TSE
disease, albeit with incubation periods of almost twice that of
wild-type mice (48–50). Our studies were maintained to approx-
imately 700 dpi, almost twice the incubation period of sCJD in G2
mice, which also show 50% PrPC expression. Thus, factors other
than a reduction in PrPC expression level are likely to contribute to
the resistance of these mice to TSE disease. While the lower ex-
pression of PrPC in G2mice may contribute to the longer incuba-
tion period observed in this model after challenge with vCJD, the
G2 mice are more susceptible to infection with the sCJDMM2-
and G2-passaged 263K TSE agents despite expressing lower levels
of PrPC than wild-type controls. Therefore, this enhanced suscep-
tibility can be directly attributed to the altered glycosylation status
of the host.
The monoglycosylated sCJDMM2 agent was transmitted to a
normally resistant host (51) by removal of the glycans at PrP res-
idue 196 (as removed in G2 mice). Moreover, sCJDMM2 became
adapted in the G2 host and produced very short incubation times
on the second pass. The data suggest that the presence of glycans at
PrP residue 196 (as present inG1 orwild-typemice) is responsible
for the sCJDMM2 transmission barrier; removal of this site may
facilitate the interaction between hostmonoglycosylated PrPC and
the infective monoglycosylated PrPSc, allowing replication of the
infective agent. This is the first time that glycosylation-deficient
transgenic mice have shown an enhanced susceptibility to TSE
infection compared to that of wild-type mice. This suggests that
glycosylation at the second glycosylation site can protect against
transmission both between and within species.
Experimental transmissions from wild-type or G2 mice in-
fected with the 263K strain provide additional evidence that sim-
ilar glycosylation statuses of host PrPC and the PrPSc in the inoc-
ulated strain can greatly accelerate TSE incubation periods.
Indeed, the incubation period in G2 recipients was almost half
that of wild-type mice after challenge with the G2-263K strain.
In both primary and secondary passages of vCJD, incubation
periods were shorter in wild-type mice than in mice in which the
second PrPC N-glycan attachment site was disrupted. The shorter
incubation periods were observed irrespective of the glycosylation
status of the second site in the infecting PrPSc. While these differ-
ences in incubation time can be explained on the basis of lower
PrPC expression levels in the G2 mice, we cannot discount the
possibility that it indicates a preference of this strain for a PrPC
diglycosylated host irrespective of the passage history of the
strain. This may explain the ability of this agent to infect a large
number of host species and its transmissibility across many
species barriers.
G1 and G3 mice showed little susceptibility to infection
throughout this study. Indeed, these transgenic mice did not de-
velop any pathologically confirmed clinical TSE disease after in-
oculation with any of the three agents used, although asymptom-
atic infection in the form of PrP deposition was detected in
extremely low numbers. This may be linked to an inability of this
particular host PrPC to propagate nonmurine strains; previous
experiments performed with a number of mouse-adapted scrapie
strains by several routes have highlighted an intrinsic resistance of
both G1 and G3 mice to infection (23, 52). Therefore, it is more
likely that the resistance observed in G1 and G3mice in this study
is linked to a more general mechanism rather than an effect of the
species barrier. Why the absence of the first glycosylation site
should lead to such a dramatic loss of host susceptibility may be
related to the conversion efficiency of PrPC to PrPSc. Some in vitro
conversion assays have previously suggested that glycosylation in-
hibits the conversion activity (30). However, such in vitro systems
have not revealed the complexity of the glycosylation issue ob-
served in these in vivo studies. The resistance observed in the G3
mice likely is related to the absence of the G1 glycosylation. How-
ever, G3 mice also showmore C1-truncated PrPC upon biochem-
ical analysis than G1, G2, and wild-type mice. Previous in vitro
studies have shown that higher levels of C1 PrPC are associated
with resistance to TSE infection (53). In addition, G3 mice show
the lowest PrPC expression of the three glycosylationmutants and
a different PrPC localization (22). All of these factors might con-
tribute to the resistance to TSE infection of this specific line of
mice.
The absence of glycans at the second site may alter the biology
of PrPC or PrPSc interaction in a very different way than that of the
first glycosylation site. A number of biochemical properties and
the cellular localization of PrPC in the G2 mice resemble that ob-
FIG 4 PrPC expression levels in the brains of glycosylation-deficient trans-
genic mice. RepresentativeWestern blots showing the different PrPC isoforms
in wild-type (Wt), G1, G2, and G3 mice using BC6 (A) and BH1 (B) antibod-
ies. Western blots underwent densitometry to measure levels of PrPC. -Tu-
bulinwas used as a loading control. The different isoforms of PrPC are denoted
Di (for diglycosylated), Mono (monoglycosylated), Un (unglycosylated), and
C1 frag. (C1 fragments).
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served in wild-type and G1 mice (22). However, the presence/
absence of carbohydrates in a specific portion of PrPC may influ-
ence other characteristics, such as the ultrastructural localization
of PrPC (e.g., localization in a different portion of the cell mem-
brane) or its conformation, and this may dictate the different sus-
ceptibility to infection of the G2 mice compared to that of the G1
mice.
We have argued that altered glycosylation status of PrPC alters
the host susceptibility. An alternative explanation is that the point
mutations inserted in order to modify the N-linked glycosylation
sites on PrP are the cause of this change (22). Previous transmis-
sion studies performed by us (23) and Neuendorf et al. (20) have
shown similar results upon primary passage of both ME7 and
mouse BSE strains with prolonged incubation periods in mice
deficient at the first glycosylation site despite utilizing different
amino acid substitutions and expressing different levels of PrP. In
addition, Ikeda et al. (54) showed that substitution of Asn residues
to abolish glycosylation sites does not prevent conversion of PrPC
to PrPSc. In this study, the differences between the wild-type and
G2 hosts in susceptibility to primary passage with two human
agents, vCJD and sCJDMM2 (characterized by an identical PrPSc
sequence and PK cleavage pattern but a different glycoprofile),
further argues for the glycosylation status being the main deter-
minant of host susceptibility rather than the change in amino acid
sequence.
The deposition of PrP in the brains of G2 mice infected with
vCJD differed from that observed in wild-type mice infected with
the same agent. First, the total amount of PrP that accumulated by
disease endpoint appeared to be lower in G2 mice. This could be
due to less PrPC being available for replication, or it could mean
that the rates of misfolding, clearance, and/or toxicity of PrP are
changed in the absence of glycosylation at the second site. In ad-
dition, small PrP aggregates were observed in G2 mice infected
with vCJD, in contrast to the diffuse PrP deposition observed in
wild-type mice. Large aggregated deposits of PrP also were ob-
served in G2 mice challenged with sCJDMM2. These data suggest
that PrPC that lacks the second glycosylation site has altered mis-
folding or clearance kinetics, which also may have an important
effect on host susceptibility.
In summary, we propose that the transmission of TSE agents
across different species can be profoundly influenced by post-
translational events in both PrPC and PrPSc. In particular, we have
demonstrated that the glycosylation status of host PrPC (55, 56)
can dramatically alter cross-species transmission characteristics
and likely is important for this protein to act as a receptor for the
incoming TSE agent.
On the other hand, the prevalence of certain PrPSc gly-
cotypes in an infectious inoculum may determine its confor-
mation and the ability to interact with the host and cause a TSE
infection. This combination may lead to the binding between
PrPSc and PrPC occurring through direct interactions between
the glycan residues and/or different PrP regions that have been
recently suggested to be important for TSE transmission be-
tween different species (57) or by interactions with a number of
conversion cofactors previously suggested, such as host pro-
teins or nucleic acids (58–60).
The dramatic effects in altered host susceptibility, in particular
the resistance of the G1 and G3 mice to infection, suggests this
mechanism provides an important focus for blocking the disease
process and protecting the infected individual from neurodegen-
eration.
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